Future Market Insights (FMI), a leading market research firm, forecasts a robust future for the Global Dengue Vaccines Industry. Their new analysis projects the market to reach a staggering US$ 1,603.7 million by 2033, driven by a significant double-digit Compound Annual Growth Rate (CAGR).
Key pharmaceutical companies, having successfully concluded clinical trials, are gearing up for potential new product launches. Analysts express optimism about the imminent expansion of the growth horizon within the Dengue vaccine industry. The strategic insights provided by FMI underscore the industry’s potential to address the rising prevalence of dengue fever, particularly in the Asia-Pacific region.
The Asia-Pacific region has witnessed a surge in the incidence of dengue fever, escalating the demand for effective medicines and vaccines to combat this viral disease. Against this backdrop, some pharmaceutical companies are focusing on the development of innovative dengue vaccines. FMI’s latest report highlights a positive trajectory for the Global Dengue Vaccines Industry, with a projected total valuation of US$ 474.8 million expected in 2023.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1763
Geographic Overview
Latin America is expected to remain the second largest market for dengue vaccines, with a valuation of nearly US$ 290 million by the end of the forecast period. The report also predicts that more pharmaceutical companies will become involved in the expansion of the Global Dengue vaccine industry shortly.
According to the report, government institutes will continue to be the largest end-users of dengue vaccines. Dengue vaccine sales across government institutes will generate nearly US$650 million in revenue by the end of 2027. Furthermore, hospitals will maintain their dominance, with double-digit CAGRs throughout the forecast period. Sales of the sole vaccine, Dengvaxia, manufactured by Sanofi, are currently driving market growth. Furthermore, the factors influencing the market growth profiled in the report are discussed below.
Key Highlights of Global Dengue Vaccines Industry Report
- Other than the burdening occurrence of dengue in some countries, the economic turmoil in Latin America is estimated to influence the growth of the global market at the macroeconomic level.
- Live attenuated vaccines are also produced and developed economically, thereby consoling the vaccine market and patients.
- Low availability of optimum diagnostic systems and lack of skilled professionals have led to cases, where dengue fever is being treated as undistinguished febrile disease.
- The global market of dengue vaccines is likely to secure an opportunistic revolution when companies are likely to able to successfully develop effective vaccines for all age groups.
Overall, the global dengue vaccines market, which is currently valued at nearly US$ 250 million, will increase rapidly to reach over US$ 1,250 million in terms of revenues, by the end of 2027.
Talk to Analyst
https://www.futuremarketinsights.com/ask-question/rep-gb-1763
According to FMI’s report, the following dengue vaccine manufacturers operate within the Global Dengue Vaccines Industry landscape:
- Sanofi Pasteur Limited
- Takeda Pharmaceutical Company Limited
- Merck & Co. Inc.
- GlaxoSmithKline Plc.
- GeneOne Life Science Inc.
- Medigen Vaccine Biologics Corporation
- Panacea Biotec Limited
- Sun Pharmaceutical Industries Ltd
- Serum Institute of India Pvt. Ltd.
- Biological E Ltd.
Global Dengue Vaccines Industry Key Segments Covered
Product
- CYD-TDV (Dengvaxia)
End-User
- Hospitals
- Government Institutes
- Non-governmental Organizations (NGOs)
Region
- North America (US and Canada)
- Latin America (Brazil, Mexico, Venezuela, and the Rest of LATAM)
- Western Europe (Germany, UK, France, Spain, Italy and Rest of Western Europe)
- Eastern Europe (Russia, Poland and Rest of Eastern Europe)
- APEJ (The Philippines, Indonesia, Malaysia, Thailand, Vietnam, India and Rest of APEJ)
- Japan
- Middle East & Africa (GCC, Northern Africa, South Africa and Rest of MEA)
Click Here To Buy Your Detailed Report
https://www.futuremarketinsights.com/checkout/1763
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube